{"podcast":{"title":"BioSpace","slug":"biospace-6696251","podcast_index_feed_id":6696251,"rss_url":"https://api.riverside.fm/hosting/3SxyDAXU.rss","website_url":"https://www.biospace.com/","image_url":"https://hosting-media.riverside.com/media/imports/podcasts/a2a52916-bfe1-4f2a-b9a3-9be5029ecbe4/39510587-1699400129885-1e919ae7cb2aa.jpg","author":"BioSpace","episode_count":247,"summary":"Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.","last_synced_at":"2026-07-15T16:19:04.105662+00:00","page_url":"https://stenobird.com/podcast/biospace-6696251"},"episode":{"title":"From sequence to scale: Gene editing’s new era in biologics manufacturing","slug":"from-sequence-to-scale-gene-editing-s-new-era-in-biologics-manufacturing","published_at":"2026-07-10T14:29:33+00:00","page_url":"https://stenobird.com/podcast/biospace-6696251/from-sequence-to-scale-gene-editing-s-new-era-in-biologics-manufacturing","show_page_url":"https://stenobird.com/podcast/biospace-6696251","url":"https://api.riverside.com/hosting-analytics/media/e6ef3999a4eebc7ff3d3fb7d2bd2283cc2faf6faa7941b683026532cd64aee24/eyJlcGlzb2RlSWQiOiIzNmJlMDE4OC02M2QxLTRmMzQtYmNlOS1iYzM0MzdmNzBjOTciLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmE1MTAyMTE4ZmM0NGVmMzc1MWUzM2MxL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi03LTEwX18xNi0zMC00MS5tcDMifQ==.mp3","audio_url":"https://api.riverside.com/hosting-analytics/media/e6ef3999a4eebc7ff3d3fb7d2bd2283cc2faf6faa7941b683026532cd64aee24/eyJlcGlzb2RlSWQiOiIzNmJlMDE4OC02M2QxLTRmMzQtYmNlOS1iYzM0MzdmNzBjOTciLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmE1MTAyMTE4ZmM0NGVmMzc1MWUzM2MxL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi03LTEwX18xNi0zMC00MS5tcDMifQ==.mp3","summary":"In this episode of Denatured, you’ll hear from Jack Crawford, CEO of Demetra, and Magnus Gustavsson, chief commercial officer at NorthX Biologics. We unpack the evolution of cell line development — CHO cells, targeted integration, transposases and the collaboration models speeding biologics from sequence to GMP. Host Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Jack Crawford , CEO, Demeetra Magnus Gustafsson , Chief Commercial Officer, NorthX Biologics Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.","meta_description":"In this episode of Denatured, you’ll hear from Jack Crawford, CEO of Demetra, and Magnus Gustavsson, chief commercial officer at NorthX Biologics. We unpa…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1241,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/from-sequence-to-scale-gene-editing-s-new-era-in-biologics-manufacturing/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/biospace-6696251/from-sequence-to-scale-gene-editing-s-new-era-in-biologics-manufacturing.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}